Akebia Therapeutics Inc (AKBA):企業の財務・戦略的SWOT分析

◆英語タイトル:Akebia Therapeutics Inc (AKBA) - Financial and Strategic SWOT Analysis Review
◆商品コード:GDPH136059FSA
◆発行会社(調査会社):GlobalData
◆発行日:2021年4月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD600 ⇒換算¥88,800見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD900 ⇒換算¥133,200見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Akebia Therapeutics Inc (Akebia Therapeutics) is a biopharmaceutical company focused on the development and commercialization of novel therapeutics based on hypoxia inducible factor for patients with kidney disease and other metabolic disorders. Its lead product candidate vadadustat is a HIF-PH inhibitor, a regulator for the production of red blood cells, or RBCs, in the body, as well as other important metabolic functions for the treatment of anemia due to chronic kidney disease (CKD). The company’s product pipeline includes AKB-5169, an oral treatment for inflammatory bowel disease. The company works in partnership with Otsuka Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, and Vifor Pharma Management Ltd for the development and commercialization of its pipeline products. The company has its operations in the US and Ireland. Akebia Therapeutics is headquartered in Cambridge, Massachusetts, the US.

Akebia Therapeutics Inc Key Recent Developments

Mar 25,2021: Akebia Therapeutics Announces Poster Presentations and Educational Symposium at National Kidney Foundation 2021 Virtual Spring Clinical Meetings
Mar 02,2021: Akebia Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference
Feb 25,2021: Akebia reports fourth quarter and full-year 2020 financial results and provides business updates

This comprehensive SWOT profile of Akebia Therapeutics Inc provides you an in-depth strategic analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

This company report forms part of GlobalData’s ‘Profile on Demand’ service, covering over 50,000 of the world’s leading companies. Once purchased, GlobalData’s highly qualified team of company analysts will comprehensively research and author a full financial and strategic analysis of Akebia Therapeutics Inc including a detailed SWOT analysis, and deliver this direct to you in pdf format within two business days. (excluding weekends).

The profile contains critical company information including*,

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Note*: Some sections may be missing if data is unavailable for the company.

Key benefits of buying this profile include,

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

【レポートの目次】

Table of Contents

Section 1 – About the Company

Akebia Therapeutics Inc – Key Information
Akebia Therapeutics Inc – Overview
Akebia Therapeutics Inc – Key Employees
Akebia Therapeutics Inc – Key Employee Biographies
Akebia Therapeutics Inc – Key Operational Heads
Akebia Therapeutics Inc – Major Products and Services
Akebia Therapeutics Inc – History
Akebia Therapeutics Inc – Company Statement
Akebia Therapeutics Inc – Locations And Subsidiaries
Akebia Therapeutics Inc
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Akebia Therapeutics Inc – Business Description
Akebia Therapeutics Inc – Corporate Strategy
Akebia Therapeutics Inc – SWOT Analysis
SWOT Analysis – Overview
Akebia Therapeutics Inc – Strengths
Akebia Therapeutics Inc – Weaknesses
Akebia Therapeutics Inc – Opportunities
Akebia Therapeutics Inc – Threats
Akebia Therapeutics Inc – Key Competitors

Section 3 – Company Financial Performance Charts

Akebia Therapeutics Inc – Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts

Section 4 – Appendix

Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

Note*: Some sections may be missing if data is unavailable for the company

List of Tables

Akebia Therapeutics Inc, Key Information
Akebia Therapeutics Inc, Key Ratios
Akebia Therapeutics Inc, Share Data
Akebia Therapeutics Inc, Major Products and Services
Akebia Therapeutics Inc, History
Akebia Therapeutics Inc, Key Employees
Akebia Therapeutics Inc, Key Employee Biographies
Akebia Therapeutics Inc, Key Operational Heads
Akebia Therapeutics Inc, Other Locations
Akebia Therapeutics Inc, Subsidiaries
Akebia Therapeutics Inc, Key Competitors
Akebia Therapeutics Inc, SWOT Analysis
Akebia Therapeutics Inc, Ratios based on current share price
Akebia Therapeutics Inc, Annual Ratios
Akebia Therapeutics Inc, Interim Ratios
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

★海外企業調査レポート[Akebia Therapeutics Inc (AKBA):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Sedia Biosciences Corp:製品パイプライン分析
    Summary Sedia Biosciences Corp (SBC) is a medical device company that offers diagnostic products. The company provides medical devices, diagnostic devices, HIV incidence products, rapid point of care assays and specimen collection devices. It also offers diagnostic products, epidemiological products …
  • IRWIN Industrial Tool Co:企業の戦略的SWOT分析
    IRWIN Industrial Tool Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products a …
  • Chegg, Inc.:企業のM&A・事業提携・投資動向
    Chegg, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Chegg, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, ca …
  • Credit Suisse Group AG:企業のM&A・事業提携・投資動向
    Credit Suisse Group AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Credit Suisse Group AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions …
  • West Japan Railway Co (9021):企業の財務・戦略的SWOT分析
    West Japan Railway Co (9021) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Karus Therapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Karus Therapeutics Ltd (Karus) is a drug development company that designs and develops cancer therapies. The company offers small molecule drugs with immunotherapy for the treatment of hematological and solid tumors. Its pipeline products include KA2507 and KA2237 inhibitors. Karus’ KA2507 i …
  • Gannett Co Inc (GCI):企業の財務・戦略的SWOT分析
    Gannett Co Inc (GCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • FleetPride, Inc.:企業のM&A・事業提携・投資動向
    FleetPride, Inc. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's FleetPride, Inc. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), dives …
  • Corcept Therapeutics Inc (CORT):企業の財務・戦略的SWOT分析
    Corcept Therapeutics Inc (CORT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weak …
  • Sinochem International Corp (600500):企業の財務・戦略的SWOT分析
    Sinochem International Corp (600500) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …
  • POP Biotechnologies Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary POP Biotechnologies Inc (POP Biotechnologies) is a biotechnology company that develops and harnesses nano-scale technologies. The company’s product portfolio comprises of NP-01, an encapsulated nanoparticle used to impart systemic drug release; and C36 product, a cobalt indulged nanoparticle …
  • Northern Trust Corporation:企業の戦略・SWOT・財務情報
    Northern Trust Corporation - Strategy, SWOT and Corporate Finance Report Summary Northern Trust Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • INFINITT Healthcare Co., Ltd (071200):企業の財務・戦略的SWOT分析
    INFINITT Healthcare Co., Ltd (071200) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths an …
  • Vattenfall:企業の戦略・SWOT・財務情報
    Vattenfall - Strategy, SWOT and Corporate Finance Report Summary Vattenfall - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …
  • Institute for Research in Immunology and Cancer-製薬・医療分野:企業M&A・提携分析
    Summary Institute for Research in Immunology and Cancer (IRICoR), a subsidiary of University of Montreal is a non-profit research institute that offers drug discovery and commercialization services. The institute offers discovery, development and commercialization of novel drugs in oncology. It has …
  • 3M Co (MMM):電力:M&Aディール及び事業提携情報
    Summary 3M Company (3M) is a diversified technology company that specializes in the development, manufacture and marketing of a wide range of innovative products. The company develops technology platforms, including adhesives, abrasives, light management, microreplication, non woven materials, nanot …
  • Definiens AG:製薬・医療:M&Aディール及び事業提携情報
    Summary Definiens AG (Definiens), a subsidiary of AstraZeneca Plc, is a healthcare technology company that offers image analysis and data mining solutions. The company offers products such as tissue studio, developer, image miner, server, architect and viewer, among others. Its services include cons …
  • Etiqa Insurance Berhad:企業の戦略的SWOT分析
    Etiqa Insurance Berhad - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Logicor Europe Ltd:企業の戦略的SWOT分析
    Logicor Europe Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …
  • Bunzl plc (BNZL)-医療機器分野:企業M&A・提携分析
    Summary Bunzl plc (Bunzl) is a global distribution and outsourcing company that supplies a broad range of non-food products to a diverse market sectors. The company offers an array of food packaging, disposable tableware and catering equipment, cleaning and hygiene supplies, guest amenities, persona …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆